Paramount Global Statistics
Total Valuation
Ocugen has a market cap or net worth of $321.67 million. The enterprise value is $327.48 million.
Important Dates
The last earnings date was Friday, August 1, 2025, before market open.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 312.30 million shares outstanding. The number of shares has increased by 12.21% in one year.
| Current Share Class | 312.30M |
| Shares Outstanding | 312.30M |
| Shares Change (YoY) | +12.21% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 18.22% |
| Float | 287.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.48 |
| Forward PS | 268.40 |
| PB Ratio | 98.61 |
| P/TBV Ratio | 105.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 68.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.83, with a Debt / Equity ratio of 10.75.
| Current Ratio | 1.83 |
| Quick Ratio | 1.50 |
| Debt / Equity | 10.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.75 |
Financial Efficiency
Return on equity (ROE) is -569.99% and return on invested capital (ROIC) is -116.04%.
| Return on Equity (ROE) | -569.99% |
| Return on Assets (ROA) | -73.55% |
| Return on Invested Capital (ROIC) | -116.04% |
| Return on Capital Employed (ROCE) | -155.56% |
| Revenue Per Employee | $50,042 |
| Profits Per Employee | -$599,853 |
| Employee Count | 95 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.77% in the last 52 weeks. The beta is 3.85, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 3.85 |
| 52-Week Price Change | -20.77% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 51.31 |
| Average Volume (20 Days) | 2,913,195 |
Short Selling Information
The latest short interest is 54.76 million, so 17.53% of the outstanding shares have been sold short.
| Short Interest | 54.76M |
| Short Previous Month | 56.13M |
| Short % of Shares Out | 17.53% |
| Short % of Float | 19.04% |
| Short Ratio (days to cover) | 13.59 |
Income Statement
In the last 12 months, Ocugen had revenue of $4.75 million and -$56.99 million in losses. Loss per share was -$0.20.
| Revenue | 4.75M |
| Gross Profit | -29.58M |
| Operating Income | -55.39M |
| Pretax Income | -50.86M |
| Net Income | -56.99M |
| EBITDA | -52.34M |
| EBIT | -55.39M |
| Loss Per Share | -$0.20 |
Full Income StatementBalance Sheet
The company has $27.01 million in cash and $32.82 million in debt, giving a net cash position of -$5.81 million or -$0.02 per share.
| Cash & Cash Equivalents | 27.01M |
| Total Debt | 32.82M |
| Net Cash | -5.81M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 3.05M |
| Book Value Per Share | 0.01 |
| Working Capital | 14.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$51.72 million and capital expenditures -$579,000, giving a free cash flow of -$52.30 million.
| Operating Cash Flow | -51.72M |
| Capital Expenditures | -579,000 |
| Free Cash Flow | -52.30M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,165.08% |
| Pretax Margin | -1,197.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
| Earnings Yield | -17.72% |
| FCF Yield | -16.26% |
Analyst Forecast
The average price target for Ocugen is $6.00, which is 482.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 482.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 185.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -9.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.42 |
| Piotroski F-Score | 2 |
